Report #2835208

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 12 yrs
State: TX
Recovered: Unknown
Vaccinated: Mar 28, 2025
Onset: Mar 28, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (ENGERIX-B)	GLAXOSMITHKLINE BIOLOGICALS	5	H39Z4	—

Symptoms (1)

Extra dose administered

Symptom narrative

5 doses administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 12-year-old male patient who received HBV (Engerix B) (batch number H39Z4, expiry date 04-DEC-2025) for prophylaxis. On 28-MAR-2025, the patient received the 5th dose of Engerix B. On 28-MAR-2025, an unknown time after receiving Engerix B, the patient experienced extra dose administered (Verbatim: 5 doses administered). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 28-MAR-2025 On 28th March 2025, a nurse called to inform that earlier that day, a patient had received a dose of Engerix-B but had already completed their vaccination series, making it an additional dose. The reporter confirmed that it had been the fifth dose of Engerix-B the patient had received, which led to Extra dose administered.